zanidatamab (Ziihera)

Indications

• previously treated, unresectable or metastatic HER2-positive cancer
  • HER2-positive biliary tract cancer

* FDA approved with a companion diagnostic device from Ventana Medical/ Roche Diagnostics to identify eligible patients

Monitor

• left ventricular ejection fraction prior to & at regularly during treatment

Adverse effects

• infusion-related reactions
• diarrhea, abdominal pain, fatigue

* boxed warning for embryo-fetal toxicity

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• binds to two extracellular sites on HER2

More general terms

• antineoplastic monoclonal antibody